Director, Solid Tumor Program

 

Education/Training

Undergraduate:
Graduate School: University of Hacettepe, School of Medicine, Ankara, Turkey
Residency: Pediatrics, Hacettepe Children’s Hospital, Ankara; Pediatrics, Children’s Hospital of Los Angeles
Fellowships: Pediatric Hematology/Oncology/BMT, Children’s Hospital of LA

 

Board Certifications

Pediatric Hematology/Oncology

 

Areas of Interest and Expertise

Neuroblastoma

 

Selected Publications

Yu, A.L., Gilman, A., Ozkaynak, M.F., et al.: Anti-GD2 antibody with GM-CSF, interleukin-2 and isotretinoin for neuroblastoma. N Engl J Med 363:1324-1334, 2010; 24(3):176-81. doi: 10.1111/tme.12123. Epub 2014 May 2. PMID: 24786047.

Halicka, H.D., Ozkaynak, M.F., Levendoglu-Tugal, O., Sandoval, C., Seiter, K., Kajstura, M., Traganos, F., Jayabose, S. and Darzynkiewicz, Z. DNA damage response as a biomarker in treatment of leukemias. Cell Cycle 8:11, 1-5,2009.

Ozkaynak, M.F. Favorable outcome of primary CNS anaplastic large cell lymphoma in an immunocompetent patient. J Pediatr Hematol Oncol, 31: 128-130, 2009.

Gilman, A.L., Ozkaynak, M.F., Matthay, K., Krailo, M., Yu, A., Gan, J., Sternberg, A., Hank, J., Seeger, R., Reaman, G., Sondel, P. Phase I study of ch14.18 with GM-CSF and IL-2 in children with neuroblastoma following autologous bone marrow transplant or stem cell rescue: A report from the Children’s Oncology Group. J Clin Oncol, 27:85-91, 2009

Ozkaynak, M.F., Sahdev, I. , Gross, T.G., Levine, J., Cheerva, A., Richards M.K., Rozans, M.K., Shaw, P.J., Kadota, R.P. A Pilot Study of Addition of Amifostine to Melphalan, Carboplatin, Etoposide and Cyclophosphamide with Autologous Hematopoietic Stem Cell Transplantation in Pediatric Solid Tumors – A Pediatric Blood and Marrow Transplant Consortium Study. J Pediatr Hematol Oncol 30: 204-209, 2008.

Satwani, P., Sather, H., Ozkaynak, F., Heerema, N.A., Schultz, K.R., Sanders, J., Kersey, J., Davenport, V., Trigg, M., Cairo, M. Allogeneic bone marrow transplantation in first remission for children with ultra-high-risk features of acute lymphoblastic leukemia: A Children’s Oncology Group study report. Biol Blood Marrow Transplant, 13: 218-227, 2007.

Carr, E., Jayabose, S., Stringel, G., Slim, M., Ozkaynak, M.F., Tugal, O., Sandoval, C. The safety of central line placement prior to treatment of pediatric acute lymphoblastic leukemia. Pediatr Blood Cancer,47:886-888, 2006.

Jayabose, S., Levedoglu-Tugal, O., Ozkaynak, M.F., Sandoval, C. Recurrent immune thrombocytopenic purpura in children. Pediatr Hematol Oncol, 23:677-682, 2006.

Pine, S.R., Guo, Q., Yin, C., Jayabose, S., Levendoglu-Tugal, O., Ozkaynak, M.F., Sandoval, C. GATA1 as a new target to detect minimal residual disease in both transient leukemia and megakaryoblastic leukemia of Down syndrome. Leuk Res, 29:1353-1356, 2005.

Ozkaynak, M.F., Krailo, M., Feusner, J. Randomized comparison between antibiotics alone and antibiotics plus granulocyte-colony-stimulating factor in pediatric patients with chemotherapy induced febrile neutropenia: A report from the Childrens Oncology Group. Pediatr Blood Cancer, 45: 274-280, 2005.